Objectives-To investigate the prevalence of human papillomavirus (HPV) infections in a group of female teenagers, and to analyse to what extent HPV DNA was also detectable, in urethra and cervix samples among the patients with macroscopic genital warts compared with those without.
Design-The patients were interviewed about their sexual habits and history of venereal diseases. They underwent a gynaecological health control examination, including macroscopic inspection for genital warts and collection of a cytological vaginal smear (Pap smear). Cell samples were also taken from endocervix and urethra and from vulva lesions, when found. These samples were tested for HPV DNA of the types 6, 11, 16, 18 and 33 using the polymerase chain reaction (PCR) technique. Setting-An adolescence out-patient clinic in Malmo, Sweden. Subjects-Forty-nine female teenagers consulting for gynaecological complaints, some of them for genital warts. Results-Twenty patients had present and four had a history of genital warts (group A). The other 25 patients had no visible lesions (group B). In the first group (A) 18 of the 24 patients were positive for HPV DNA in one or more of the three locations studied. More patients were positive in urethra (17) than in cervix (15) . In group B four of the 25 patients were positive for HPV DNA in urethra, three of these also in cervix. In the two groups 11 and four patients, respectively, showed pathological Pap smears.
Conclusions-The finding of HPV DNA in urethra, both from women with and without visible genital warts, indicates that there is a high probability that the infection is also present in cervix, sug 
Samples
A speculum was inserted into the vagina, and after macroscopic inspection ordinary Pap smears were taken from vagina and ectocervix with a wooden spatula and from endocervix with a brush (Cytobrush, Medscand, Sweden). With the speculum still in vagina, cell samples for HPV DNA analysis were collected from the endocervix using the Cytobrush. Cell sample from urethra was collected with a cotton swab and from visible warts (lesions) with the use of the Cytobrush. All samples were collected strictly in this order. Two of the patients with a history of vulval condylomata but with no visible warts had a test from the previous wart area, as identified by the patients. Discomfort was felt only from the urethra sampling, being equivalent to a chlamydia test. Samples for gonococci and chlamydia were not taken. Patients with pathological Pap smears were subject to a second examination and cell sampling approximately three months later.
HPV DNA analysis by polymerase chain reaction (PCR). 9 The cell samples for HPV DNA tests were suspended in physiological saline and then sent to the laboratory. After being pelleted by centrifugation (4 000 x g, 5 min) the cells were digested by proteinase K (1-6 mg/ml) overnight at 37°C. After heat inactivation of the proteinase ( ) . Also, the overlay of paraffin oil in the PCR tubes was applied to the reagent mix before the patient material was added.
Statistical analyses
Differences in HPV prevalence between the groups were evaluated using the Fisher's exact test and the Mann-Whitney U test.
Results
The age of the patients, their age at sexual debut and the number of life time sexual partners were similar in the two groups of patients. There was a wide range in the number of partners, from two to twenty, and in the estimated total number of coitus, from ten to 750, but with no differences between the two groups. The mean number of life time sexual partners of the group A patients' present partners was significantly higher than that of the partners of the group B patients, 109 versus 6.3 (p < 0.05) (table 2) Among the 24 patients with current or previous condylomata (group A) 18 (75%) were shown to harbour HPV infections in one or more locations. Fifteen (63%) of the cervix and 17 (71%) of the urethra samples contained HPV DNA. Fourteen patients were positive for HPV DNA both in cervix and urethra and in all cases at least one HPV type was the same at both sites. Eleven patients had identical combinations of HPV types in urethra and cervix. In samples collected from the lesions of 19 patients 13 (68%) were positive. Twelve (63%) of the 19 patients were positive for HPV DNA in all three locations, four of the 24 patients were positive in two and in two of the patients HPV DNA was detected in only one site. Eleven (46%) of the patients of group A had pathological Pap smears, ten classified as CIN 1 and one as CIN 2. All of these patients were positive for HPV DNA except for one with CIN 1 diagnosis.
Four (16%) of the 25 patients of group B were positive for HPV DNA, three in both cervix and urethra and one in the urethra sample only. The patients with abnormal cytology at first examination were followed up with new Pap smears approximately three months later. Of those 13 patients with CIN 1 at the initial test, six showed CIN 1, one CIN 3 and six had normal cytology at the second test. HPV DNA was detected in five, one and three of the patients in the respective groups. The two women with CIN 2 diagnosis at the first examination showed CIN 1 and CIN 2 at the second examination.
Discussion
The female teenagers who participated in this study are not representative for all teenagers in Malmo or Sweden. Both groups, with and without visible condylomata, came from a sub-population probably with earlier sexual debut, higher number of partners and higher prevalence of sexually transmitted diseases than the general population. Furthermore, many of the patients visited the adolescence clinic because of suspected genital warts. The age at first intercourse was equal to a group of patients treated for chlamydia infections at the same clinic (Ericsson, C., personal communication). The number of sexual partners ranged from two to twenty, but there was no difference between those with and without visible warts. However, the mean estimated number of life time sexual partners of the group A patients' present partners was significantly higher than that of the patients of group B, stressing that not only the woman's sexual experience but also the sexual history of her partner is very important.
Despite all STD information and campaigns to use condoms as protection against infections ("safe sex"), condom use is not common among the teenagers. The majority of the girls use birth control pills, and it is difficult to motivate both female and male teenagers to use condoms as prophylaxis against STD infections.
The Although it is not possible in every single case to rule out that local contamination from the cervix to urethra might have taken place during the examination, despite digital separation of labia minor and insertion of the speculum in a vertical-down movement, it seems unlikely to be an explanation of the HPV DNA findings from urethra. The reliability of the urethra HPV DNA results is further supported by results from analysis of urine specimens and urethra brush samples collected in this order from both men and women, showing good correlation between the HPV DNA findings of the paired samples (Forslund, 0., to be published).
In patient group A, where the prevalence of HPV DNA was much higher (75%) than in group B (16%), the prevalence of pathological Pap smears was also much higher compared with group B, 46% and 16%, respectively, confirming the correlation between HPV infections, condylomata and cervical dysplasia. HPV 16, the main malig-nancy associated HPV type, predominated among the patients with abnormal Pap smears, and was the most common type in all three locations analysed (fig b) . In the group with normal Pap smears HPV 6 was the single most common type, although infections with HPV16, 18 and 33 taken together were almost as prevalent as HPV 6 and 11 together (fig a) . There was a good agreement between the cytological primary screening and the rescreening. All cases reported as CIN 1 or benign with cellular changes associated with HPV infection would have been classified as squamous intraepithelial lesion (SIL), low grade, according to the suggested Bethesda system. 7 From our data it is apparent that the HPV infections in patients with condylomata acuminata not only are present in the visible warts and the area around them, but are also often found in the cervix uteri and in the urethra. Since parallel findings of HPV DNA in these sites, generally with one or more types in common, were most prevalent, the detection of HPV infection in one genital location makes it highly probable that the same type of HPV is present in other genital sites, too. Subclinical HPV infections of the vulva have also been found to coexist in high frequency with HPV infections and precancerous lesions of the cervix.'8 Thus, the HPV infection in the genitourinary tract, in this sense, is most often not only a local but a regional or multifocal infection.
When HPV DNA can be detected in urethra cell samples collected with a brush or a swab, as in this study, the same HPV type can generally also be found in cells from urine specimens from the same patient (Forslund, 0. et al, manuscript in preparation). Therefore, at least in epidemiological surveys, HPV DNA analysis of urine might become a convenient, non-invasive method of choice applicatory to individuals of all ages.
There are still many unanswered questions regarding the implications of genital HPV infections. Can treatment of a condyloma of the vulva change the prognosis of the patient, when the infection is also present in other sites such as urethra and cervix? To which extent should the type of HPV influence treatment and follow up of the infection? What happens when condylomata disappear after laser therapy? Is the immune response against the viral infection activated? How should the male partners to HPV infected women be approached? Should they be tested, and if found HPV positive, can and should they be treated?
To investigate the long time effects of genital HPV infections, the female teenage patients of this study will be followed longitudinally concerning cytological changes and presence of HPV DNA.
